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ABSTRACT
Background: Ablative therapies have been used for the treatment of neurological disorders for many
years. They have been used both for creating therapeutic lesions within dysfunctional brain circuits
and to destroy intracranial tumors and space-occupying masses. Despite the introduction of new
effective drugs and neuromodulative techniques, which became more popular and subsequently
caused brain ablation techniques to fall out favor, recent technological advances have led to the resur-
gence of lesioning with an improved safety profile. Currently, the four main ablative techniques that
are used for ablative brain surgery are radiofrequency thermoablation, stereotactic radiosurgery, laser
interstitial thermal therapy and magnetic resonance-guided focused ultrasound thermal ablation.
Object: To review the physical principles underlying brain ablative therapies and to describe their use
for neurological disorders.
Methods: The literature regarding the neurosurgical applications of brain ablative therapies has been
reviewed.
Results: Ablative treatments have been used for several neurological disorders, including movement
disorders, psychiatric disorders, chronic pain, drug-resistant epilepsy and brain tumors.
Conclusions: There are several ongoing efforts to use novel ablative therapies directed towards the
brain. The recent development of techniques that allow for precise targeting, accurate delivery of ther-
mal doses and real-time visualization of induced tissue damage during the procedure have resulted in
novel techniques for cerebral ablation such as magnetic resonance-guided focused ultrasound or laser
interstitial thermal therapy. However, older techniques such as radiofrequency thermal ablation or
stereotactic radiosurgery still have a pivotal role in the management of a variety of neurological
disorders.
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Introduction
The aim of ablative therapies for neurological disorders is
the selective destruction of a targeted volume of cerebral tis-
sue [1,2]. Several ablative procedures, based on various phys-
ical principles, have been used to date in the field of
neurosurgery. These techniques are used both to create
therapeutic lesions in the brain to interrupt maladaptive
cerebral networks and to destroy abnormal tissue such as in
brain tumors. Ablative procedures fell out of favor in the
1950s and 1960s due to the introduction of more effective
drugs for the treatment of neurological disorders, and again
in the 1990s with the development of neuromodulative pro-
cedures. However, in the last decade, recent advances in
imaging and lesioning technologies have rekindled interest
in lesioning for the treatment of many neurological disorders
[3]. The aim of this article is to briefly describe the physical
principles and techniques that have been adopted for cere-
bral ablation and to review their neurosurgical applications.
Ablative techniques for brain surgery
Physical principles used for brain ablation have included
chemical agents, mechanical devices, ionizing radiation,
induction of heat or cryogenics, high-intensity focused ultra-
sound (HIFU), electromagnetic waves and radiofrequency
(RF) [4]. Currently, the four main ablative techniques that are
used for brain pathologies are RF thermoablation, stereotac-
tic radiosurgery (SRS), laser interstitial thermal therapy (LITT),
and HIFU thermal ablation [3] (Table 1).
Radiofrequency thermal ablation
The interstitial RF technique consists of creating a lesion
using heat through an intracranially placed electrode
coupled to an RF generator (Figure 1). This electrode is elec-
trically insulated except at the tip, where the active electrode
is located. When the generator is activated, the electric cur-
rent flows in the circuit between the active and dispersive
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electrodes. The electric field between the two contacts oscil-
lates with the RF frequency and causes the nearby charged
ions in the electrolyte medium to move back and forth
in space at the same high frequency, which is typically
about 500,000 cycles per second for most modern genera-
tors. The frictional heating within the tissue resulting from
the RF ionic oscillation, i.e., the current density, is the basic
mechanism by which the tissue heats up and by which the
RF heat lesion is made. The greatest heating takes place in
the region of highest current density, which is near the tip
of the active electrode [5,6].
Laser interstitial thermal therapy
Lasers are a form of nonionizing radiation that produces a
coherent and collimated beam of light energy. Their effect
on tissues is due to two principles: absorption and scatter.
Absorption is the conversion of laser energy to heat after the
laser’s photons collide with molecules in the target tissue
called chromophores (oxyhemoglobin and deoxyhemoglobin
are the key absorbers). This energy transfer to chromophores
causes the release of heat and subsequent damage to adja-
cent cells and structures. Scatter occurs when a photon’s tra-
jectory is deviated by interacting with particles in the tissue,
resulting in an increased spatial distribution of light and
heat [7,8].
After more than 50 years of technological development,
lasers are used for stereotactic ablations in the form of mag-
netic resonance imaging (MRI)-guided LITT. In this technique,
laser light is transmitted interstitially (an applicator is
inserted into the target volume) through flexible fiberoptic
wires coupling the generator to the patient’s tissue [7,8].
MRI-guidance and MR thermography combined with dedi-
cated software allow precise, real-time monitoring of the pro-
cedure and direct visual feedback regarding the three-
dimensional (3D) distribution of the induced thermal tissue
damage, thus providing an opportunity to avoid injury to
functionally important brain structures [8,9]. LITT also offers
the ability to produce lesions of various volumes and shapes
by modifying the laser probe position along the planned tra-
jectory [10].
Radiosurgery
SRS is an external ablative treatment modality that delivers a
large single dose of radiation to a limited intracranial target
volume while sparing surrounding tissue. Computerized dos-
imetry planning and highly accurate radiation delivery
Table 1. Advantages and disadvantages of the ablative techniques currently used in brain surgery.
RF thermoablation Radiosurgery LITT MRgFUS thermal ablation
Advantages  Distinct lesion borders
 Intraoperative physiological
confirmation
 No limitation of the region of
treatment
 Immediate results
 External
 No limitation of the region of
treatment
 Ablation of a large tissue
volume
 Conformation of the lesion to
complex geometries
 Radiobiologic effect is slower
and may allow for more
plasticity
 Distinct lesion borders
 No limitation of the region of
treatment
 Ablation of a large tissue
volume
 Real-time monitoring of
lesioning process with MRI
and thermometry
 Immediate results
 Distinct lesion borders
 Intraoperative physiological
confirmation
 External
 Real-time monitoring of lesion
process with MRI and
thermometry
 Immediate results
Drawbacks  Surgical risk (intracerebral
hemorrhage, loss of accuracy)
 Less predictability of lesion
size and shape
 Requires multiple passes for
the ablation of large volumes
 Delayed effect
 Graduated dose fall-off and
less demarcated lesion
borders
 Exposure to ionizing radiation
 No intraoperative feedback
 Surgical risk (intracerebral
hemorrhage, loss of accuracy)
 Requires multiple passes for
the ablation of large volumes
 MRI environment
 Limited to central areas of the
brain
 Head must be shaved
 Uncomfortable for
claustrophobic patients
 Increased operative times
 MRI environment
Abbreviations: RF: radiofrequency; LITT: laser interstitial thermal therapy; MRgFUS: magnetic resonance-guided focused ultrasound; MRI: magnetic resonance
imaging.
Figure 1. A neurosurgeon performing a stereotactic procedure at the hospital
“Istituto Neurologico Carlo Besta” in Milan in the early 1980s.
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systems are necessary to achieve this effect [11,12]. Target
location is defined by image-guided stereotaxy [13]. In SRS,
energy is delivered to the target in the form of ionizing radi-
ation, which is any radiant entity that has enough energy to
remove an electron from an atom, thus creating ions. In
turn, these charged particles interact with the living tissue in
the target and generate a biologic response such as cell
death or halted mitosis [12]. Currently, several devices are
used to perform SRS procedures, with each of them based
on a different source of ionizing radiation. For example,
Gamma Knife radiosurgery (GKRS), developed by Lars Leksell,
takes advantage of gamma rays originating from the excited
nuclei of 60Co. Linear accelerators are a more cost-effective
alternative for SRS and generate a single high-energy X-ray
beam that is focused by special collimators with the intent
to narrow, modulate or shape the beam to the tissue volume
[12,13].
Focused ultrasound thermal ablation
MR-guided focused ultrasound (MRgFUS) is a novel, noninva-
sive technique used for thermal ablation. In this procedure,
HIFU beams are targeted to an intracranial region using a
hemispheric phased-array of transducers that is fixed to the
skull. This allows the passage of ultrasonic waves through
the maximum available skull area, thus avoiding overheating
and brain damage. The device is also coupled with a dedi-
cated software that allows for the correction of phase distor-
tions and aberrations of ultrasonic beams that are produced
by the irregularities of the skull (Figure 2) [14]. Ultrasonic
mechanical energy is absorbed within the focal target vol-
ume and converted into heat that causes tissue destruction
locally at the focus [1]. At the same time, MRI-guidance and
MR-thermography allow for accurate targeting and real-time
monitoring of energy deposition [15].
Movement disorders
Essential tremor (ET) is the most common movement dis-
order and is typically characterized by unilateral or bilateral
postural and kinetic tremor of the upper extremities [16].
Parkinson’s disease (PD) is a neurodegenerative disorder in
which patients classically exhibit progressive tremor, rigidity,
bradykinesia and postural instability [17]. In the early twenti-
eth century, open ablative procedures for PD and ET were
carried out at the level of the precentral gyrus, cerebral
peduncles and other parts of the pyramidal tract with con-
siderable neurological side effects [18–22]. It was the com-
bination of work by Russel Meyers in the 1930s (by lesioning
the extrapyramidal system) and Ernest Spiegel and Henry
Wycis in the 1940s (by developing modern stereotactic
methods) that allowed for reliable, safe and effective lesion-
ing techniques for movement disorders [23,24]. Irving
Cooper carried out the first successful thalamotomies and
pallidotomies for the treatment of both tremor and PD in
the 1950s. While cerebral lesioning fell out of favor with the
discovery of levodopa replacement for PD in the 1960s and
then again with the advent of deep brain stimulation (DBS)
in 1990s, advanced imaging technologies have made thala-
motomy, pallidotomy and subthalamotomy all viable options
for patients with medically intractable tremor and PD who
prefer not to or cannot safely undergo surgical implantation
of hardware for neuromodulation (Figure 3) [25,26]. Dystonia
is a movement disorder characterized by sustained or inter-
mittent muscle contractions causing abnormal, often repeti-
tive movements, postures or both [27]. In the mid-20th
century, it was treated more often with stereotactic
Figure 2. A simulation of a stereotactic MRgFUS ablative procedure with the Kranion software. Temperature prediction is showed on the left side of the panel
(maximal: red, average: green). MRgFUS: magnetic resonance-guided focused ultrasound.
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thalamotomy than pallidotomy [28]. This trend continued up
to the 1990s. After then, the success of pallidotomy in reliev-
ing dyskinesias and dystonia in PD was demonstrated, and
posteroventral pallidotomy was used with striking benefit
also in patients affected by primary generalized dystonia
[29–32]. Thereafter, pallidal DBS rapidly replaced pallidotomy
Figure 3. Axial (left) and coronal (right) T2-weighted MRIs demonstrating unilateral thalamotomy (A), pallidotomy (B), and subthalamotomy (C) using transcranial
MRgFUS. MRI: magnetic resonance imaging; MRgFUS: magnetic resonance-guided focused ultrasound.
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due to reversibility of stimulation [33]. Today pallidotomy is
still indicated, in particular for dystonic patients who present
in emergency situations such as status distonicus, patients
who experience severe DBS hardware-related adverse effects
requiring the removal of their implant and in those who
exhibit poor nutritional status with poor wound healing or
very thin skin that would be incompatible with a DBS sys-
tem [34–37].
Thalamotomy
Surgical lesioning of the ventral intermediate (Vim) nucleus
of the thalamus has been shown to provide significant rates
of tremor control for patients with ET and tremor-dominant
Parkinson’s disease (TDPD). In a retrospective study of 60
patients with medically refractory PD, ET or tremor from trau-
matic brain injury who underwent RF thalamotomy, Jankovic
et al. demonstrated that over 80% of PD and ET patients had
moderate to complete improvement in tremor at a mean fol-
low-up of 53months [38]. These findings are supported by
similar studies examining RF thalamotomy for PD and/or ET,
showing moderate to complete tremor improvement in
60–100% of cases at last follow-up [39–43]. Most adverse
events with RF thalamotomy are transient as a result of per-
ilesional edema that subsides over time; however, persistent
ataxia, dysarthria and motor/sensory deficit may occur [44].
The risk of dysarthria is significantly higher with bilateral
lesions [40]. Therefore, RF thalamotomy is generally only per-
formed unilaterally.
Other means for thalamotomy include GKRS and transcra-
nial MRgFUS, which obviate the risk of intracranial hemor-
rhage and infection seen in open surgical procedures [45]. A
prospective study by Ohye et al. utilizing GKRS thalamotomy
for 72 patients with ET or PD demonstrated meaningful
tremor improvement in 81% of the 53 patients who followed
up at 24months [46], although other similar prospective
studies were less promising [47,48]. There are several retro-
spective studies of GKRS for ET demonstrating meaningful
tremor improvement in 69–96% of patients [49–51]. MRgFUS
allows for immediate lesioning, and its efficacy for treating
tremor associated with ET and PD has been demonstrated in
two randomized, sham-controlled clinical trials. In 76 patients
who underwent this procedure for ET, Elias et al. demon-
strated 47% improvement in mean tremor scores and 59%
reduction in mean disability scores at three months postop-
eratively [52]. This benefit was sustained at two-year follow-
up [53]. Bond et al. performed a similar study in 27 patients
with TDPD, demonstrating 62% improvement in median
tremor scores from baseline at 3months postoperatively
(22% in the sham group) [54]. As a result of these trials,
MRgFUS is currently approved by the FDA for the treatment
of both ET and TDPD.
Pallidotomy
Ablation of the globus pallidus internus pars interna (GPi)
has been shown to ameliorate the cardinal motor symptoms
of PD, including tremor, rigidity and bradykinesia [55].
Pallidotomy may also reduce levodopa-induced dyskinesias
[56]. While originally proposed by Leksell in the 1950s,
Laitinen et al. reintroduced the posteroventral pallidotomy in
the 1990s for the symptomatic treatment of PD. The postero-
ventral lesions performed by this surgeon were more effect-
ive on all symptoms of PD and resulted in a lesser degree of
cognitive impairment than the lesions previously targeted to
the anteromedial and dorsal regions of the GPi. Among the
32 patients in this study, 92% and 81% had almost complete
resolution of rigidity/bradykinesia and tremor, respectively, at
a mean follow-up of 28months [57]. Subsequent randomized
controlled trials demonstrated improvements in the off-medi-
cation Unified Parkinson’s Disease Rating Scale (UPDRS) Part
III by 31–65% at follow-up of 6–12months [56,58,59].
Pallidotomy carries similar motor and cognitive risks as thala-
motomy, although there is also the risk of visual disturbance
[60]. MRgFUS has been explored as a noninvasive means
of pallidotomy [61,62], and there is currently a large, multi-
center trial underway to determine its efficacy. Finally,
pallidotomy has been used for the treatment of dystonia.
Considering studies that evaluated patients with standar-
dized measures between 1996 and 2007, 12 patients with
primary generalized dystonia experienced a 61% decrease in
the Burke–Fahn–Marsden dystonia rating scale (BFMDRS),
whereas there was only a 20% average decrease in patients
with secondary dystonia [31]. In contrast to patients with PD,
the procedure for primary dystonic patients is usually bilat-
eral, as most of these patients have axial and bilateral
extremity symptoms and are better able to tolerate bilateral
lesioning. Although most experience comes from RF lesion-
ing, more recently, LITT has been used as a more controlled
means for performing pallidotomy in the treatment of dys-
tonia and has yielded good preliminary results [63].
Subthalamotomy
Following research from the 1980s that revealed the over-
active state of the subthalamic nucleus (STN) in PD, RF sub-
thalamotomy was explored for the symptomatic treatment of
the motor symptoms of PD [64]. More recent uncontrolled
and randomized controlled trials of RF subthalamotomy have
yielded improvements in off-medication UPDRS Part III scores
in the range of 43–52% at 12 months follow-up [65,66].
Contralateral dyskinesias and transient hemiballism have
been reported following subthalamotomy, although there
appears to be less risk of neurocognitive issues as compared
to pallidotomy [60,65]. MRgFUS subthalamotomy was
studied in an open-label trial of 10 patients by Martinez-
Fernandez et al., demonstrating a total reduction of off-medi-
cation UPDRS Part III by 35% and mean levodopa equivalent
dosage reduction of 24% [67]. A randomized, multicenter
trial is currently underway to further assess the efficacy of
this procedure.
Psychiatric disorders
The study of functional neuroanatomy led to the belief that
removing or destroying specific regions of the brain could
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alter behavior [68]. Originally, psychosurgery was often car-
ried out in an indiscriminate way, with frequent and severe
side effects, lack of precision, no regulatory oversight and
often bad outcomes, thus casting a shadow over the field.
Thereafter, the adoption of stereotactic methodology and
more strict patient selection criteria led to the improvement
of safety and outcomes [68–70].
Major depressive and obsessive–compulsive disorders
Obsessive–compulsive disorder (OCD) is characterized by
repetitive and intrusive thoughts and behaviors that cause
clinically significant distress or impairment [71]. Major
depressive disorder (MDD) includes depressive symptoms for
a continuous period of at least two weeks that are unrelated
to other causes, such as bereavement or other mood disor-
ders [72]. To address these symptoms, three main cerebral
sites have been targeted and four distinct ablative operations
have been performed, as shown in Tables 1 and 2 [68].
Anterior capsulotomy
The term anterior capsulotomy (AC) refers to lesioning of the
anterior limb of the internal capsule (ALIC) just superior to
the ventral striatum (Figure 4). This procedure is intended to
interrupt communication between the orbitofrontal cortex,
cingulate cortex, ventral striatum and thalamus [68,71]. A
recent literature review of observational studies involving AC
via SRS or RF techniques for OCD reported a full response
rate (>35% Y-BOCS reduction) of 54% with a transient and
permanent adverse events rate of 56.2% and 21.4%, respect-
ively [71]. AC appeared more effective if performed bilaterally
[70,73]. More recently, two large studies of GKRS capsulot-
omy confirmed AC as a safe, effective and long-lasting pro-
cedure for patients with OCD (in one of these studies,
benefit persisted at five years) [74,75]. AC has also been suc-
cessfully used for the treatment of MDD [70]. Most recently,
MRgFUS was used to perform AC in four patients with refrac-
tory OCD and in one patient with MDD, successfully control-
ling symptoms for both indications [76,77].
Subcaudate tractotomy
Subcaudate tractotomy (SCT) was introduced by Geoffrey
Knight in 1964 and aims to selectively interrupt white matter
tracts connecting the orbitofrontal cortex and subcortical
limbic structures. The target is an area inferior to the head of
the caudate nucleus overlying area 13 of the orbitofrontal
cortex, which posteriorly includes the substantia innominata
[78,79]. Originally, Knight adopted a freehand technique
for implanting bilateral B-emitting yttrium 90 (90Y) seeds.
Subsequently, the stereotactic technique was introduced and
90Y seeds were replaced with RF coagulation. Overall,
40–60% of the >660 patients who were operated on for
affective disorders (MDD and bipolar disorder), OCD and
other anxiety disorders at the Brook General Hospital in
London led normal or near-normal lives at the one-year post-
surgical assessment. The procedure was relatively devoid of
complications (one death from >660 cases examined, with
1.6% experiencing epilepsy as the most frequent complica-
tion) [68]. In 1975, Goktepe et al. found a 50% improvement
after a long period of follow-up in 208 OCD patients treated
with SCT [80]. More recently, Kim reported positive results in
a small series of patients undergoing SCT [81], and one OCD
patient was successfully treated with MRI-guided SCT, thus
supporting the current value of this procedure [82].
Figure 4. Axial T1-weighted MRI sequence demonstrating bilateral anterior
capsulotomy using stereotactic radiosurgery for obsessive-compulsive disorder.
MRI: magnetic resonance imaging.
Table 2. Lesion procedures.
Procedure Indications Method Target Side effects
Anterior capsulotomy OCD RF, SRS Anterior limb of internal
capsule
Weight gain, fatigue, memory
loss, incontinence, seizure
Anterior cingulotomy OCD, MDD, BD RF Anterior cingulate Seizure
Subcaudate tractotomy OCD, MDD, BD, anxiety Yttrium-90 rods with RF, RS Substantia innominata Seizure
Limbic leucotomy OCD, MDD, BD Mechanical disruption, heat,
radioactive materials, RF
Anterior cingulate, substantia
innominata
Lethargy, perseveration,
incontinence, somnolence,
apathy, seizure
Abbreviations: OCD: obsessive-compulsive disorder; MDD: major depressive disorder; BD: bipolar disorder; RF: radiofrequency; SRS: stereotactic radiosurgery;
Y-BOCS: Yale-Brown obsessive-compulsive scale.
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Anterior cingulotomy
Anterior cingulotomy (ACT) involves lesioning of the dorsal
anterior cingulate cortex and anterior cingulate bundle.
These fibers carry information from the cingulate cortex to
the orbitofrontal cortex and limbic system [68,71]. ACT was
introduced as an open technique, which was associated with
significant mortality and morbidity [73,83]. However, after
the adaptation of stereotactic techniques, it was demon-
strated to be a safe and effective procedure in a large num-
ber of patients with psychiatric illness, to the point that it
was the procedure of choice for OCD and MDD patients in
North America for more than 30 years [69,73,83]. A recent lit-
erature review of the SRS and RF ACT observational studies
for OCD reported a full response rate (>35% Y-BOCS reduc-
tion) in 41% of patients, with transient and permanent
adverse events rates of 14.3% and 5.2%, respectively [71].
When patients with MDD undergoing ACT are considered, a
literature review showed an improvement of standardized
outcomes ranging from 39–65% [70].
Limbic leucotomy
Kelly introduced stereotactic limbic leucotomy (SLL) in 1973
as a combination of bilateral ACT and SCT [84]. The rationale
was that the dual lesions in the lower medial quadrant of
the frontal lobe would produce better results than either sin-
gle lesion. The first lesion in the subcaudate area was
thought to sever frontolimbic connections, whereas the cin-
gulate lesion was intended to disconnect Papez circuit
[68,69,73]. Several techniques were used to carry out SLL,
including wire loops, blunt instruments, cryoablation (Kelly’s
original technique), radioactive materials and more recently
MRI-guided RF thermoablation [85]. Various studies showed
encouraging results both in the treatment of MDD and OCD
patients [70,85,86].
Addiction
Addiction is defined as a behavior in which an individual has
impaired control resulting in harmful consequences [87].
Stereotactic lesioning surgery was widely adopted for its
treatment. Leucotomy, hypothalamotomy, ACT and lesions in
the nucleus accumbens (Nac) were consequently performed
with varying degrees of success [88]. More recently, 335
drug-addicted patients underwent bilateral cryocinguloto-
mies in Russia. Despite a reported successful outcome in
about 60% of patients, the Russian government stopped the
study due to a lack of a clear evidence for efficacy and safety
concerns [89]. Likewise, in China, beginning in the year 2000,
bilateral RF ablation of the Nac was performed in 28 patients
to treat heroin addiction. Eleven patients did not relapse dur-
ing the 15 months follow-up period, and they showed an
improvement in several psychological domains without cog-
nitive impairment. The therapeutic effect was considered to
be excellent (7 patients) or good (10 patients) in 65.4% of
patients. However, also in this case, the Chinese government
halted the study in 2004 due to several limitations, including
the nonblinded nature of the study, the absence of a control
group and the small number of patients [90].
Eating disorders
Anorexia nervosa (AN) is characterized by an extremely low
body mass index (BMI) (<18.5 kg/m2) and concomitant anx-
iety and preoccupations related to weight and body image.
To date, six studies have examined the role of ablative
procedures in patients with severe AN [91]. The targets for
ablation were the frontal lobe white matter [86,92], the dor-
somedial thalamus [93] and more recently the ALIC [94,95]
and Nac [96]. The first five of these papers are case reports
or small series and show variable results in terms of weight
gain and psychiatric improvement. More recently, Liu et al.
have reported on a large group of 76 patients who under-
went RF AC and have been followed for a relatively long
period (3 years). In this study, the authors reported excellent
results in terms of weight gain normalization and comorbid
psychiatric symptomatic improvement (BMI had increased
from 13.6 ± 1.6 to 19.3 ± 3.6 kg/m2 with 46 patients reaching
a healthy BMI >18.5 kg/m2, and there was a significant
improvement in validated scores of anxiety, depression and
social function). However, the study was criticized due to the
lack of disease-specific scales to analyze the important cogni-
tive and behavioral aspects of AN, as well as the lack of a
control group [95].
Morbid obesity (mOB) is defined by a BMI >40 or >35 kg/m2
in the presence of a significant obesity-related comorbid con-
dition [91]. To date, one study explored brain ablation for this
disorder. In 1974, Quaade et al. reported on three patients
undergoing stereotactic RF ablation of the lateral hypothal-
amus in an area where electrical stimulation was able to
evoke hunger-related responses, which were not further
specified. These patients showed a statistically significant, but
transient, decrease from preoperative to postoperative spon-
taneous calorie intake, while body weight decreased slightly
and temporarily, not being significantly affected [91,97].
Aggressive and disruptive behavior
Aggressive behavior was defined by Sano as ‘behavior that
leads to damage or destruction of some objective and is not
necessarily considered to be provoked in the usual sense’
[98]. This behavior is thought to result from a disturbance of
the delicate balance between various neuronal circuits in the
hypothalamic–limbic system. In the past century, stereotactic
lesioning of the amygdala and the hypothalamus were the
main procedures performed to address this condition. Other
operations, such as ACT and AC, were carried out in smaller
groups of patients [99,100].
Patients selected for hypothalamotomy or amygdalotomy
were usually cognitively impaired and had low IQ, even
though patients without cognitive deficits were treated as
well [100]. The procedures were performed bilaterally in
staged or single sessions, and they could be combined in
refractory patients [100]. Ramamurthi et al. reported on a ser-
ies of 603 patients with aggressive behavior disorder who
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were treated with stereotactic amygdalotomies and hypo-
thalamotomies. Success was sustained in 70% of patients at
three years, with no deterioration in IQ or behavior [100].
Likewise, Sano published a series of 37 patients undergoing
hypothalamotomy for aggressive behavior. The results were
considered to be satisfactory in 29 cases (78%) and were sta-
ble after a 10-year follow-up period. Several other smaller
series of patients have been treated with hypothalamotomy
and amygdalotomy, with satisfactory clinical improvement in
80% or more of patients [98]. However, all these series lack
detailed information on their measuring instruments, report-
ing of side effects, and stringent monitoring by an ethics
committee. These requirements were met by a recent study
on bilateral combined AC and ACT, which reported a signifi-
cant reduction of aggressiveness and improvement in social
and family relationships in 10 patients [101].
Tourette syndrome
Tourette syndrome (TS) is a chronic neurodevelopmental dis-
order characterized by motor and phonic tics that, by defin-
ition, occurs with a childhood onset [102].
Many ablative procedures were performed to treat intract-
able TS. Initially, frontal lobotomies and leucotomies were
predominantly carried out [103]. Subsequently, these proce-
dures were abandoned in favor of less destructive and more
accurate stereotactic operations, such as chemothalamec-
tomy by Cooper et al. in 1962 [104], or lesioning of the
intralaminar and medial thalamic nuclei by Hassler and
Dieckmann in 1970 [105]. Thereafter, numerous cerebral sites
were lesioned alone or in a combined manner, with mixed
results. Ablated structures included thalamic nuclei, struc-
tures of the limbic system, Forel’s field, the zona incerta and
the dentate nucleus of the cerebellum [106]. However, it is
unclear how the authors were certain of their target localiza-
tion, and in some articles, the target is not even mentioned.
In addition, there was a lack of criteria according to which
the diagnosis of TS was made, and, finally, the tic evaluation
methods were frequently not reported [106]. Today, DBS has
replaced lesioning surgery for TS, although the ideal target
has not been defined as of yet [107].
Chronic pain
Pain is regarded as chronic when it lasts or recurs for at least
three months [108]. Since the beginning of the last century,
many ablative procedures have been performed for the
treatment of chronic pain. Thalamotomy, mesencephalotomy
and cingulotomy have been the most frequent (Table 3),
whereas lesions in the pulvinar, the hypothalamus, the pituit-
ary, the frontal lobe, the primary motor cortex and the pri-
mary sensory cortex (SI) have been much less common. In
the last two decades, the use of these techniques has been
significantly reduced due to the advent of neuromodulatory
techniques and intrathecal opiate pumps [109]. Nevertheless,
contemporary interest in stereotactic destructive lesions to
control pain is again growing as new and safer technologies
have been developed and the limits of neurostimulation
have emerged [110].
Thalamotomy
Stereotactic thalamotomy was performed extensively in the
early years of human stereotaxis [111] as it provided signifi-
cantly less surgical and neurological morbidity than proce-
dures performed at the pontine or mesencephalic level [112].
At first, lesions were made in the lateral sensory thalamic
nuclei (ventroposterolateral and ventroposteromedial nuclei).
Subsequently, due to an excessively high rate of somatosen-
sory sequalae associated with these lesions, many surgeons
targeted the medial thalamic nuclei (centralis lateral nucleus,
Table 3. Most common brain ablative procedures performed for chronic pain.
Site of lesion
Stereotactic coordinates for lesion
placement, mm lateral/antero-posterior/
verticalþ ant and sup, - post and inf Side effects
Intraoperative positive effects to
stimulation
Posterior central-lateral nucleus 6/2 posterior to PC/ 0 Somatosensory deficits, pretectal
deficits
Paresthesias, dysesthesias, pain relief
Cm/Pf 8–10/5 anterior to PC/þ4 Somatonsensory deficits, oculomotor
deficits/ verbal deficits
Tingling/painful burning sensation/
unpleasant sensations (throbbing,
pulling)
Lateral sensory thalamus
VPL 17/3 anterior to PC/þ10 Somatosensory deficits, paresthesia,
dysesthesia, central pain
Limbs paresthesia
VPM 10/2 anterior to PC/þ17 Somatosensory deficits, paresthesia,
dysesthesia, central pain
Face paresthesia
Anterior cingulate fasciculus þ5–7/20–25 posterior to the anterior
tip of the frontal horn/1–2 above
the roof of the lateral ventricle
Decreased attention, apathy, decreased
spontaneity, impairment of executive
functions, seizures
Short-term verbal memory deficit
Mesencephalon 5–10/5 posterior to PC/–5 Oculomotor disturbances, dysesthesias,
ipo-anesthesia, ipo-analgesia, motor
weakness
Tremor (medial lemniscus), burning
pain, numbness, cold sensation
(spinothalamic tract), vibration, pain,
funny feeling, panic,
hyperventilation, involuntary
verbalization, pulse and respiration
slowing, emotional reactions
(reticular formation,
periaqueductal gray)
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centromedian/parafascicular complex, posterior complex, the
medial pulvinar [112–115] and the posterior central lateral
nucleus (CLp)) [114], which relieved pain without inducing
any clinically detectable sensory loss or central pain
[111,115]. Nonspecific medial thalamic nuclei are intercon-
nected with associative and paralimbic areas of the brain,
and the stimulation or lesioning of these areas is thought to
address predominantly the affective-motivational component
of chronic pain. Conversely, surgeries directed in the lateral
thalamus directly interrupt the somatotopically arranged
ascending pain pathways as they enter the thalamus.
Accordingly, the effect of these surgeries is thought to result
from an influence on the sensory-discriminative component
of pain [116]. Finally, the posterior complex and CLp nuclei
are considered to have an intermediate functional role
between diffuse and nondiffuse nuclei and project to large
cortical domains, including areas mediating discriminative
(SI), affective-motivational (anterior cingulate cortex insula),
cognitive (prefrontal cortex) and motor (premotor cortex)
aspects of pain [114]. Their surgical lesioning is therefore
thought to have a multimodal effect. The most recent study
targeting the mesial thalamus with SRS showed that >50%
pain relief was achieved in 67% of patients, with 20% of
patients achieving complete relief [117]. Similar results were
observed in the largest trial of centrolateral thalamotomy,
which reported that more than 50% of patients had >50%
pain relief and 20% had complete pain relief [118]. Despite
variable results in terms of pain relief and side effect profiles
(Table 2), a high rate of pain recurrence following ablative
thalamic lesions has been commonly reported by authors,
especially in the management of pain of benign origin [112].
Cingulotomy
The rationale for performing ACT in the treatment of pain is
to interrupt the afferent fibers connecting the midline thal-
amic nuclei to limbic and anterior cingulate cortex structures,
and, therefore, influence the affective component of pain
[119,120]. The earliest study of stereotactic ACT for pain was
Foltz and White’s report on the treatment of 16 patients
with pain and strong emotional factors augmenting their
symptoms [121]. These authors observed excellent, good or
fair pain relief in 14 out of 16 patients. Thereafter, the good
safety and efficacy profile of the procedure was confirmed
by several series of, usually bilateral, ACT. Subjects of these
procedures were preferentially terminally ill patients with
intractable cancer pain [122]. Particularly, those with malig-
nant diseases of the head and neck were included, in which
a psychogenic element arising from intolerable suffering
caused by aspiration, choking, dysarthria or respiratory prob-
lems was thought to be consistent and intertwined with
pain [120]. In 2002, Abdelaziz et al. reviewed all 394 patients
undergoing ACT reported up to that point. In patients with
pain of benign origin, ACT was useful in 121 (53%) and not
useful in 109 patients (47%). In patients with pain of malig-
nant origin, the procedure was useful in 80 (52%) and not
useful in 73 patients (48%). Overall, 53% of patients experi-
enced benefit from the procedure [120]. However, most of
the data were derived from small clinical series with hetero-
geneous patient populations and limited follow-up, and the
initial good response to ACT was shown to wane over time
[120]. The most frequent side effects of the procedure were
cognitive, including decreased attention, decreased activity
and apathy, although cases with no adverse effects have
been documented. Most ACTs have been performed with
SRS and RF, and more recently, Patel et al. reported on three
cases of ACT for chronic pain that were successfully carried
out with LITT, thus widening the surgeon’s armamentarium
for creating these lesions [123].
Mesencephalotomy
Mesencephalotomy was originally intended as an open lesion
of the trigeminothalamic or spinothalamic tracts at a level
superior enough to treat unilateral pain involving the upper
extremity or even the head and neck [111,124]. Due to the
excessive neurological morbidity, this initial open procedure
was refined with the stereotactic technique, which resulted
in improved safety. As demonstrated by many surgeons, suc-
cessful short-term pain relief was obtained in a significant
proportion of patients (up to 85% of patients with malignan-
cies causing pain of the head, neck and upper extremities
[125], and 67% of patients with chronic pain of benign origin
[126]). However, despite successful pain relief, stereotactic
mesencephalotomy was still burdened by high rates of pain
recurrence and severe neurological side effects. Dysesthesias
and gaze disturbances were the most common, with the lat-
ter occurring in virtually every patient in whom a mesen-
cephalic tractotomy was performed [124]. Several targeting
modifications were attempted to reduce the occurrence of
those deficits [111,127,128]; however, the procedure
remained affected by significant morbidity [111,124]. Today,
when dealing with treatment-refractory head and neck pain,
most neurosurgeons have come to prefer nondestructive
techniques such as DBS or lesioning supratentorial targets,
such as the medial thalamus [117] or the anterior cingulate
bundle [123,129]. However, recent technological advance-
ments, such as high-resolution imaging techniques and new
stereotactic techniques such as MRgFUS, could make this
procedure safer and therefore could favor its return in the
current armamentarium of the neurosurgeon [130]. Recently,
a successful case of pain relief following MRI-guided RF mes-
encephalotomy was reported [131].
Drug-resistant epilepsy
Drug-resistant epilepsy may be defined as failure of adequate
trials of two tolerated and appropriately chosen antiepileptic
drugs (whether as monotherapies or in combination) to
achieve sustained control of seizures [132].
Ablative techniques comprising stereotactic RF coagula-
tion, LITT and SRS have been used for quite some time in
epilepsy surgery [133]. The main limitation of these techni-
ques is that their selectivity in creating lesions often works
against seizure remission, as many patients have epileptic
zones that exceed volumes that can be reasonably treated
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with a ‘minimally invasive’ approach [134]. On the contrary,
their advantages over open surgery are more favorable
neurocognitive outcomes, short recovery times, greater
acceptability by patients, improved cosmetic outcomes and
minimal pain [134]. Recently, MRgFUS has emerged as a
potential transcranial ablative technique for epilepsy surgery.
This therapeutic modality has the benefit that treatment can
be staged, as there is no dose-accumulation effect. However,
technological limitations prevent its application to traditional
limbic and neocortical epilepsies, as target areas are close to
the skull and heating of the bone could cause damage to
nearby neural structures [134,135]. In contrast, lesions from
tuberous sclerosis and hypothalamic hamartoma (HH), which
are centrally located, may be amenable to ultrasound abla-
tion, although no clinical studies have been conducted as of
yet [135].
Since the first ‘golden age’ of stereotaxy in the 1950s and
1960s, a large spectrum of stereotactic ablative procedures
has been performed to halt seizure propagation or ablate
epileptogenic lesions. These procedures have included denta-
tolysis, fornicotomy, thalamotomy, hypothalamotomy, amyg-
dalotomy and many others [136–138]. Today, stereotactic
ablative techniques are used for limited conditions: arterio-
venous and cavernous malformations, HHs, mesial temporal
lobe sclerosis and, to a lesser extent, complex and deep focal
cortical dysplasias, nodular periventricular heterotopias,
tuberous sclerosis [139] and subependymal giant cell astrocy-
tomas [140]. Favorable reports exist also for stereoelectroen-
cephalography-guided surgery of neocortical nonlesional
epilepsy [10].
Mesial temporal lobe epilepsy
Mesial temporal lobe epilepsy (MTLE) is generally caused by
atrophy, gliosis and selective neuronal loss within the hippo-
campus and associated limbic system [134]. Anterior tem-
poral lobectomy (ATL) has become the most commonly
performed surgery for this syndrome, as several studies have
demonstrated its efficacy [141,142]. However, many of these
studies have also documented variable postoperative cogni-
tive decline in some patients [142]. Therefore, less-invasive
surgical interventions such as selective amygdalohippocam-
pectomy or stereotactic ablative procedures were introduced.
One of these approaches is SRS. Regis et al. were the first to
use SRS for MTLE. They found that 81% of 16 treated
patients were seizure-free at 24months. Further series,
including a multicenter controlled trial (ROSE trial), confirmed
these results [143]. The ROSE trial showed that ATL has an
advantage over SRS in terms of the extent of seizure remis-
sion, whereas 78% of ATL patients achieved seizure remission
versus 52% in the SRS arm. On the contrary, cognitive out-
come was more favorable for SRS [143]. Despite the fact that
SRS avoids a craniotomy and damage to the temporal neo-
cortex, it still has shortcomings. First, SRS causes delayed
cerebral edema that often requires corticosteroids; second,
the benefits of seizure control often do not appear until
12months after treatment and are not maximal until
24months; finally, radiation effects may cause damage to the
adjacent temporal structures [142]. LITT is another emerging
minimally invasive technique for MTLE. The operative pro-
cedure, termed as selective laser amygdalohippocampectomy
(SLAH), is achieved by inserting the laser catheter along a
slightly lateralized occipital trajectory that transverses the
length of the hippocampus to the amygdala (Figure 5). In
this way, the amygdala, hippocampus and uncinate gyrus are
ablated, while adjacent temporal structures are spared. Since
2012, SLAH has had promising results for controlling epi-
lepsy, although preliminary results raise the possibility that it
may be somewhat less effective for seizure control than ATL
(54–65% seizure freedom rate of SLAH, compared with
60–80% in ATL patients [140,144]). SLAH carries the advan-
tages inherent to a minimally invasive approach and spares
the temporal neocortex and white matter tracts, thus reduc-
ing cognitive impairment (preliminary reports suggest that it
may have less of a negative impact on memory and lan-
guage function [145,146]). Moreover, repeat LITT or open sur-
gery can still be performed if the first procedure is
unsuccessful [142,147]. Up until now, evidence for the effi-
cacy of this procedure comes from case series, which have
confirmed that there is reduced morbidity using SLAH. A
large prospective cohort study (SLATE) is currently being
conducted and should clarify the role of SLAH in MTLE [142].
Hypothalamic hamartoma
HHs are developmental malformations centered around the
tuber cinereum that are associated with medically refractory
Figure 5. Axial T2-weighted MRI demonstrating left-sided amygdalohippocam-
pectomy and the associated catheter tract following LITT for MTLE. LITT: laser
interstitial thermal therapy; MRI: magnetic resonance imaging; MTLE: mesial
temporal lobe epilepsy.
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epilepsy, gelastic seizures, developmental delay and often
precocious puberty [142]. The deep location of these lesions,
which is close to several critical neural and vascular struc-
tures, has discouraged direct surgical resective approaches,
while favoring the adoption of minimally invasive ablative
stereotactic procedures or disconnecting surgery. Stereotactic
RF coagulation is one of the alternatives to surgical resection;
however, multiple probe passes are often necessary due to
the irregular conformations of HHs, and the extension of the
RF lesion cannot be accurately predicted or monitored. This
entails a risk of damaging the hypothalamus, optic pathways
and perforating arteries [142,148]. Despite this, Kaneyama
et al. recently reported a 71% seizure-free rate with little
morbidity in a large series of 100 patients who were treated
with a novel disconnecting MRI-guided RF technique. These
results suggest that modern imaging technologies could
make the traditional RF technique safer [149]. SRS is another
safe and effective alternative for HH ablation. Two prospect-
ive trials and several case series showed good results in
terms of seizure freedom and morbidity [133,148,150]. SRS is
particularly suitable to HHs as it allows the surgeon to accur-
ately conform the radiation dose to the lesion shape
[142,148]. More recently, LITT has emerged as a promising
treatment modality for HHs. The largest case series published
thus far included 71 patients. Freedom from gelastic seizures
after single or multiple laser ablations was achieved in 93%
of these patients [151]. Another case series of 18 patients
reported rates of gelastic and nongelastic seizure freedom of
81% and 56%, respectively [75]. The postoperative complica-
tion rate for LITT is lower than that of ATL, but disabling
complications may still happen [152]. However, MRI-guidance
and thermal energy monitoring keep the risk of injuring
nearby critical structures to a minimum [142].
Cavernous and arteriovenous malformations
The anticonvulsant effects of ablative SRS have been well
described for arteriovenous malformations (AVMs) and cav-
ernous malformations (CMs). Regarding AVMs, the across-
study mean seizure remission rate is 70% [134], while for
CMs it is around 50%, as demonstrated by retrospective ser-
ies. The inclusion of the hemosiderin-stained tissue surround-
ing the CM in the treatment volume seems to be associated
with a better outcome; however, the higher doses of radi-
ation needed raise concerns in terms of toxicity [134]. More
recently, CMs have been treated with LITT with 4 out of 5
patients becoming seizure-free after at least 12months of
follow-up. Perioperative hemorrhage was not observed, des-
pite the risk of bleeding inherent to the insertion of a probe
into a bed of blood vessels [153].
Brain tumors
The standard of care therapy for most primary and second-
ary brain tumors consists of a combination of resective sur-
gery, chemotherapy and/or radiation therapy. Over time,
these standard treatments have been complemented by sev-
eral thermal and nonthermal ablative procedures [9,154].
These have included cryodestruction [155], SRS and several
other techniques that increase the temperature within
tumors, such as thermal ablation attained with RF current,
microwaves [156], HIFU [157] and LITT [7].
Radiofrequency/microwaves
Among electromagnetic wave energies, both RF and micro-
waves have been delivered through interstitial applicators for
the thermal ablation of brain tumors [154,156]. These techni-
ques were used for the management of deep-seated and/or
critically located lesions, and they were coupled with MRI
guidance so as to safely and accurately reach the planned
intracranial targets [158]. Anzai et al. treated 14 lesions in 12
patients with primary and metastatic brain tumors. They
were able to achieve local control, documented with MRI, of
all treated lesions for up to 10months of follow-up [2,158].
However, the progression of RF tumor ablation into clinical
practice was halted by several shortcomings, such as the lim-
ited volume of the thermal ablation, which was unsuitable
for treating large tumors, and the impossibility of monitoring
intracranial temperature changes without invasive measures.
Laser interstitial thermotherapy
LITT for brain tumors has been used since the late 1970s
[7,159]. However, the first lasers did not enter mainstream
clinical practice at that time due to serious technological lim-
itations and the inability to control thermal damage to the
tissue [7,160]. Subsequently, probes that were able to be
cooled to prevent charring and MRI guidance with thermom-
etry were introduced. These technological advances allowed
for careful control of the extent of the ablation and to min-
imize the thermal damage to normal surrounding paren-
chyma [160]. Today, LITT is being increasingly used for
treating several types of tumors and tumor-like masses, both
as a first-line therapy and as a secondary or salvage therapy.
Focally contained, surgically inaccessible lesions are primary
targets, although LITT is being more frequently used in cases
of surgically accessible lesions. Several trials showed that
LITT is a safe and well-tolerated technique for ablating glio-
mas. Overall, LITT was demonstrated to provide prolonged
survival in patients with unresectable recurrent glioblastomas
when compared to best palliative care [161] or brachyther-
apy [9]. The main limitation of LITT in brain tumor ablation is
with the ablation of large tumors, as the ablation of larger
neoplasms carries a high risk of cerebral edema and intracra-
nial hypertension [9,159,161].
Two recent retrospective studies, although limited in
patient numbers, have demonstrated that LITT is a viable
treatment option for recurrent meningiomas, particularly
those deemed unresectable or harbored by patients whose
comorbidities prevent an invasive open resection [162,163].
Preliminary successful data regarding LITT were reported for
pediatric brain tumors, such as primitive neuroectodermal
tumor [164] and subependymal giant cell astrocytoma [165].
Finally, LITT was proven to be a low-risk and safe surgical
procedure for the ablation of radiographic lesions growing
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after SRS in patients with brain metastases (either recurrent
tumor or radionecrosis – labeled as progressive in-field recur-
rence). A recent large multicenter prospective trial showed
that LITT minimizes cognitive decline, preserves quality of
life and functional status and permits the cessation of ste-
roids in some of these patients [166]. Another study showed
that progression-free survival and overall survival were simi-
lar between patients undergoing LITT or craniotomy for
recurrent metastases or radionecrosis [167]. Finally, LITT was
also considered as a first strategy in patients with metastases
who are surgically ineligible for resection. The main compli-
cations of LITT in brain tumor cases were neurological defi-
cits (13% transient and 3% permanent), seizures, hemorrhage
(2.5%), edema, infection or technical issues (most commonly
regarding the cooling mechanism) [7].
Ultrasound
The initial use of ultrasound energy to thermally ablate cere-
bral tumors dates back to the 1980s and the 1990s. These
studies adopted computed tomography and ultrasound-guid-
ance to deliver focused ultrasound beams to intracranial tar-
gets through a surgically created cranial defect. However,
due to the lack of an accurate method to monitor intraoper-
ative temperature, this technique did not have a sustained
clinical use [14,157]. In 2006, Ram et al. performed HIFU
tumor ablation through a craniectomy in three high-grade
gliomas. All of them had relatively long-term survival after
treatment, and histological analysis confirmed the ablation,
thus providing evidence of feasibility for this modality in the
treatment of brain malignancies [14,157,168]. Subsequently,
technical advancements, such as MR-thermometry and hemi-
spheric phased-array transducers, allowed for the delivery of
focused ultrasound beams through the intact skull. Park
et al. described the effective ablation of an anaplastic
astrocytoma through the intact skull, as demonstrated by
reduced tumor volume on follow-up MRI [169]. Thereafter,
McDannold et al. began targeting deep-seated brain tumors
with the Exablate 3000 (Insightec, Tirat Carmel, Israel)
focused ultrasound system. However, this trial was halted as
one patient expired following a procedure-related hemor-
rhage, which was likely due to nonlinear effects of ultra-
sound propagation into the brain [170]. More importantly,
these studies failed to obtain thermal coagulation in the
focus due to the technical constraints of the instrumentation
[157]. In 2014, the first successful transcranial MRgFUS abla-
tion of a recurrent glioblastoma was reported [171], and no
adverse effects were seen with this trial. Three trials are cur-
rently ongoing to determine the safety and feasibility of
transcranial MRgFUS tumor ablation. Finally, ultrasound con-
trast agents are being tested in preclinical settings to
enhance the effects of ultrasound locally within the tumor.
This may also reduce the amount of acoustic energy required
for tumor ablation, thus lowering the possibility of complica-
tions [157].
Radiosurgery
SRS is used for several types of intracranial neoplasms,
mainly metastases, meningiomas, pituitary adenomas, recur-
rent gliomas and vestibular schwannomas (VS). Regarding
gliomas, a recent meta-analysis showed that SRS is a safe
and slightly effective treatment for recurrent high-grade glio-
mas, whereas it does not provide survival benefits for those
that are newly diagnosed. However, this data still need to be
validated by large prospective randomized trials [172]. The
role of SRS for brain metastases has been clarified by recent
guidelines: SRS represents a valid alternative to surgical
resection of solitary metastases when the latter is likely to
induce new neurological deficits and when tumor volume
and location are not likely to be associated with radiation-
induced injury to surrounding structures. SRS is also widely
used to deliver radiation to the surgical cavity of solitary
brain metastases, as this was proven to remarkably decrease
the risk of local recurrence. Finally, SRS alone is recom-
mended in place of whole brain radiotherapy in patients
with more than two metastases having a cumulative volume
<7mL, as this approach provides the patients with a longer
overall survival [173]. SRS is an accepted treatment for VS,
with reported 5- to 10-year tumor control rates of over 93%,
good quality of life and preservation of function following
irradiation [174]. It has also emerged as the perfect comple-
mentary adjunct for residual or recurrent tumor after sub-
total microsurgical resection. In these situations, several
studies have demonstrated local tumor control rates
between 94% and 96%, associated with a low rate of neuro-
logical morbidity [175,176].
Finally, SRS is recommended either as an upfront or adju-
vant treatment for primary and recurrent meningiomas of
different brain regions. In fact, it allows for high rates of
tumor control with a low incidence of neurological deficits
[177]. In particular, SRS is offered for the treatment of small
tumors in elderly patients, or for tumors that are not safely
accessible by surgery [178].
Future directions
There are several ongoing efforts to use novel ablative thera-
pies directed toward the brain. The recent development of
techniques that allow for precise targeting, accurate delivery
of thermal doses and real-time visualization of induced tissue
damage during the procedure have resulted in novel proce-
dures for cerebral ablation such as MRgFUS and LITT.
MRgFUS has been shown to be a valid, less-invasive method
of creating functional therapeutic lesions within dysfunc-
tional brain circuits, thus improving the condition of patients
affected by several diseases, including ET, PD and chronic
pain. This range of indications will undoubtedly widen, as
many clinical and preclinical trials are currently ongoing.
Moreover, this technique is becoming more popular in brain
tumor therapy. LITT is still in its infancy for the treatment of
many functional disorders, but the initial results are promis-
ing, and its role in treating certain types of tumors and MTLE
or HH epilepsy is being established. Older techniques such
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as RF or SRS ablation still have a pivotal role in the manage-
ment of a variety of diseases, as their safety and efficacy has
been demonstrated by long-term clinical experience. Their
widespread availability still makes them valid means in the
physician’s armamentarium.
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